Literature DB >> 6989483

Factors related to length of complete remission in adult acute leukemia.

M J Keating, T L Smith, E A Gehan, K B McCredie, G P Bodey, G Spitzer, E Hersh, J Gutterman, E J Freireich.   

Abstract

Two hundred and two adult patients with acute leukemia were analyzed to determine pretreatment and treatment factors that could predict for duration of bone marrow remission. Several factors had a significant effect on remission duration, including morphologic diagnosis (AML greater than ALL greater than AUL), initial blast cell count, age, serum LDH, fibrinogen level, labeling index, and in vitro agar colony growth. Patients who attained a remission quickly or in whom leukemic cells in blood and bone marrow were rapidly cleared had long remissions. After applying regression model fitting methods, the six major factors, in order of significance, were the initial serum LDH level, pretreatment fibrinogen level, the number of courses of treatment to obtain a remission, morphologic diagnosis, the halving rate of leukemic cells in the blood, and the age of the patient. The model derived from this study was applied to the 202 patients and suggested that patients likely to have short or long bone marrow remission can be identified.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6989483     DOI: 10.1002/1097-0142(19800415)45:8<2017::aid-cncr2820450806>3.0.co;2-c

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  23 in total

1.  Prediction of outcome by early bone marrow response in childhood acute lymphoblastic leukemia treated in the ALL-BFM 95 trial: differential effects in precursor B-cell and T-cell leukemia.

Authors:  Melchior Lauten; Anja Möricke; Rita Beier; Martin Zimmermann; Martin Stanulla; Barbara Meissner; Edelgard Odenwald; Andishe Attarbaschi; Charlotte Niemeyer; Felix Niggli; Hansjörg Riehm; Martin Schrappe
Journal:  Haematologica       Date:  2012-01-22       Impact factor: 9.941

2.  Unrelated donor transplantation for acute myelogenous leukemia in first remission.

Authors:  Qaiser Bashir; Borje S Andersson; Marcelo Fernandez-Vina; Leandro de Padua Silva; Sergio Giralt; Alexandre Chiattone; Wei Wei; Manish Sharma; Paolo Anderlini; Elizabeth J Shpall; Uday Popat; Morgani Rodrigues; Richard E Champlin; Marcos de Lima
Journal:  Biol Blood Marrow Transplant       Date:  2010-11-16       Impact factor: 5.742

3.  Reduced intensity vs. myeloablative conditioning with fludarabine and PK-guided busulfan in allogeneic stem cell transplantation for patients with AML/MDS.

Authors:  Gheath Alatrash; Kelly M Kidwell; Peter F Thall; Antonio Di Stasi; Julianne Chen; Madhushree Zope; Alyssa K Crain; Richard E Champlin; Uday Popat; Elizabeth J Shpall; Roy B Jones; Borje S Andersson
Journal:  Bone Marrow Transplant       Date:  2018-12-10       Impact factor: 5.483

4.  High-dose cytosine arabinoside intensification for acute nonlymphocytic leukemia in patients over 56 years of age.

Authors:  A Ferrant; C Doyen; A Delannoy; L Van den Bossche; P Martiat; V Deneys; M De Bruyère; A Bosly; J L Michaux; G Sokal
Journal:  Ann Hematol       Date:  1992-04       Impact factor: 3.673

5.  Pretreatment of cytokinetics in acute myelogenous leukemia. Age-related prognostic implications.

Authors:  H M Kantarjian; B Barlogie; M J Keating; R R Hall; T L Smith; K B McCredie; E J Freireich
Journal:  J Clin Invest       Date:  1985-07       Impact factor: 14.808

6.  A randomized trial of chemoimmunotherapy of acute nonlymphocytic leukemia in adults using a protein-bound polysaccharide preparation.

Authors:  R Ohno; K Yamada; T Masaoka; T Ohshima; I Amaki; Y Hirota; N Horikoshi; A Horiuchi; K Imai; I Kimura
Journal:  Cancer Immunol Immunother       Date:  1984       Impact factor: 6.968

7.  Long term follow-up of remission patients in adult acute leukemia.

Authors:  D Gerecke; M Kress; W D Hirschmann
Journal:  Klin Wochenschr       Date:  1983-10-03

8.  [Changes of therapy results in acute leukemia under different treatment schedules with special reference to gnotobiotic measures].

Authors:  H Link; H M Frauer; K Wilms; H D Waller
Journal:  Klin Wochenschr       Date:  1983-04-01

Review 9.  A critique of the role of the blood-brain barrier in the chemotherapy of human brain tumors.

Authors:  D J Stewart
Journal:  J Neurooncol       Date:  1994       Impact factor: 4.130

Review 10.  Acute myeloid leukemia in the elderly: biological features and search for adequate treatment.

Authors:  V Heinemann; U Jehn
Journal:  Ann Hematol       Date:  1991-10       Impact factor: 3.673

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.